<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[48, 53] patients with chronic immune thrombocytopenia<br>[75, 98] adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30,000 per L.<br>[266, 268] 197 patients<br></td>
<td width=33%>
[4, 7] chronic immune thrombocytopenia<br>[48, 53] patients with chronic immune thrombocytopenia<br>[75, 98] adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30,000 per L.<br>[254, 268] Between Nov 22, 2006, and July 31, 2007, 197 patients<br>[527, 538] patients who have not responded to splenectomy or previous treatment.<br></td>
<td width=33%>
[4, 7] chronic immune thrombocytopenia<br>[48, 53] patients with chronic immune thrombocytopenia<br>[75, 102] adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30,000 per L. Patients were randomly allocated<br>[140, 163] stratified by baseline platelet count ( 15,000 per L), use of treatment for immune thrombocytopenia, and splenectomy status.<br>[254, 268] Between Nov 22, 2006, and July 31, 2007, 197 patients<br>[527, 538] patients who have not responded to splenectomy or previous treatment.<br></td>
</tr>
